Single-Dose Gene Therapy for Inherited Deafness: What Regeneron's FDA Approval Means

How Does Gene Therapy Restore Hearing in Children With OTOF Mutations?

Otoferlin is a protein produced in the inner hair cells of the cochlea, where it plays a critical role in releasing neurotransmitters that carry sound signals to the auditory nerve. When both copies of the OTOF gene are defective, children are born with profound sensorineural deafness despite otherwise intact ear structures — a condition sometimes called auditory synaptopathy. Regeneron's gene therapy uses a modified adeno-associated virus (AAV) as a vector to introduce a functional OTOF coding sequence into these hair cells, allowing them to resume normal otoferlin production.

Because the full-length OTOF gene exceeds the cargo capacity of a single AAV particle, developers use a dual-vector strategy in which two viral particles each carry a portion of the gene and recombine inside the cell. The therapy is administered surgically through a single intracochlear injection during a brief outpatient procedure. Early clinical trial data published in journals including The Lancet and Nature Medicine in recent years have shown rapid hearing gains in treated children, with measurable responses emerging within weeks of a single dose.

Why Is Early Treatment Critical for Speech and Language Development?

The developing brain is most sensitive to auditory stimulation during a critical window in the first few years after birth. Without sound input, the auditory cortex can be recruited for other functions, making later acquisition of spoken language substantially more difficult. This is why newborn hearing screening programs — now standard in the United States and across much of Europe — aim to identify congenital hearing loss within the first months of life and initiate intervention as early as possible.

Historically, children with profound inherited hearing loss have been offered cochlear implants, which bypass damaged hair cells by electrically stimulating the auditory nerve. Gene therapy takes a fundamentally different approach: rather than replacing the function of the cochlea with a device, it aims to repair the underlying biology, potentially restoring a more naturalistic hearing experience. For families of children with OTOF-related deafness, the approval offers a new option that works alongside, rather than instead of, standard audiology care including early auditory-verbal therapy and language support.

What Are the Limitations and Unknowns of Cochlear Gene Therapy?

Mutations in OTOF account for only a small fraction — research suggests roughly 1 to 8 percent — of cases of congenital hearing loss, meaning most children with inherited deafness will not be eligible for this specific therapy. Comprehensive genetic testing is required to confirm OTOF-related deafness before treatment is considered. Researchers at institutions including Mass Eye and Ear and in China are developing additional AAV-based approaches targeting other deafness genes, but most remain in early clinical or preclinical stages.

Long-term durability is another open question. Although follow-up data from the first treated children show hearing gains sustained beyond one to two years, it is not yet known whether a single dose will provide lifelong benefit or whether re-treatment might eventually be needed. As with other gene therapies, pricing and insurance coverage will shape real-world access, and specialized centers with pediatric otologic surgical capability will be needed to deliver the product safely. Professional societies including the American Academy of Otolaryngology are expected to issue guidance on patient selection and follow-up in the coming months.